date
approv
antivir
drug
treatment
ebola
viru
diseas
evd
base
vitro
evid
antivir
activ
interferon
ifn
activ
ebola
viru
conduct
singl
arm
clinic
studi
guinea
evalu
safeti
therapeut
efficaci
ifn
treatment
evd
nine
individu
infect
ebola
viru
treat
ifn
compar
retrospect
match
cohort
infect
patient
receiv
standard
support
care
time
period
treatment
unit
cogniz
limit
treat
individu
evd
data
collect
cautious
consid
compar
support
care
ifn
treatment
seem
facilit
viral
clearanc
blood
appear
associ
earlier
resolut
diseas
symptom
surviv
calcul
date
consent
trial
date
admiss
control
cohort
date
death
receiv
support
care
compar
receiv
support
care
plu
ifn
given
differ
baselin
blood
viremia
control
cohort
ifntreat
cohort
addit
control
includ
subset
analysi
treatment
unit
guinea
match
ifntreat
patient
base
age
baselin
blood
viremia
subset
analys
use
expand
control
cohort
suggest
patient
without
ifn
treatment
fold
like
die
treat
view
altogeth
result
suggest
rational
clinic
evalu
ifn
zair
ebola
viru
ebov
member
filoviru
famili
caus
sever
frequent
lethal
infect
human
primat
sinc
decemb
outbreak
ebola
viru
diseas
evd
west
africa
claim
live
confirm
case
clinic
symptom
onset
evd
includ
headach
fever
asthenia
arthralgia
myalgia
gastrointestin
symptom
includ
abdomin
pain
nausea
vomit
diarrhea
develop
lead
electrolyt
imbal
associ
intravascular
volum
deplet
inde
evd
associ
profound
endotheli
dysfunct
lead
fluid
shift
may
result
cardiovascular
collaps
renal
failur
notabl
overal
fatal
rate
differ
countri
greatest
number
confirm
case
guinea
liberia
sierra
leon
variabl
extent
viremia
time
onset
support
care
level
support
care
contribut
case
fatal
ratio
absenc
approv
treatment
high
case
fatal
ratio
prompt
consider
potenti
treatment
option
includ
repurpos
approv
drug
type
interferon
ifn
exhibit
broad
spectrum
antivir
activ
demonstr
clinic
effect
hbv
hcv
influenza
virus
sarscov
product
occur
earliest
nonspecif
respons
viral
infect
directli
inhibit
viral
infect
activ
innat
adapt
immun
respons
clear
viru
inde
virus
evolv
immun
evas
strategi
specif
target
type
ifn
respons
confirm
import
ifn
antivir
immun
evas
strategi
particularli
relev
one
consid
ifn
ebov
infect
experiment
data
indic
ebov
protein
inhibit
host
cell
system
lead
type
ifn
product
also
inhibit
event
associ
ifn
respons
accordingli
earli
postexposur
treatment
type
ifn
might
overrid
inhibitori
effect
ebov
ifn
therapi
shown
prolong
surviv
rhesu
macaqu
model
lethal
evd
treatment
reduc
viremia
extend
time
death
similar
cynomolgu
model
lethal
evd
combin
monoclon
antibodi
target
ebov
zmab
protect
macaqu
lethal
evd
decreas
efficaci
treatment
delay
day
postinfect
addit
adenoviru
express
vector
zmab
extend
treatment
window
improv
protect
moreov
mice
guinea
pig
use
replicationdefici
human
adenoviru
express
recombin
alon
postexposur
treatment
elicit
full
protect
lethal
dose
mouseand
guinea
pigadapt
ebov
notabl
examin
serum
sampl
infect
individu
outbreak
sudan
ebov
uganda
reveal
surviv
patient
significantli
higher
level
within
first
day
onset
critic
ill
view
altogeth
studi
prompt
evalu
ifn
treatment
evd
studi
use
transcript
compet
viruslik
particl
infecti
egfpebola
viru
provid
evid
limit
ebola
viru
ebov
infect
vitro
show
ifn
exhibit
superior
antivir
potenc
compar
find
provid
basi
singl
arm
proofofconcept
pilot
studi
evalu
safeti
efficaci
treatment
evd
studi
undertaken
etu
close
coyah
guinea
ebola
outbreak
placebocontrol
studi
permit
guinean
health
author
due
ethic
concern
laboratori
clinic
data
ebovinfect
individu
receiv
support
care
treatment
center
period
receiv
ifn
avail
comparison
provid
preliminari
evid
support
evalu
ifn
subsequ
outbreak
given
urgent
need
introduc
drug
would
reduc
mortal
evd
ii
limit
data
clinic
biochem
paramet
associ
evd
iii
limit
care
provis
avail
treatment
unit
outbreak
studi
design
focus
object
endpoint
reduct
blood
viremia
resolut
clinic
symptom
improv
surviv
safeti
ifn
treatment
studi
protocol
initi
studi
popul
involv
patient
admit
ebola
treatment
unit
etu
rural
area
close
town
coyah
west
guinea
period
march
june
inclus
elig
criteria
ifn
therapi
symptom
onset
within
day
blood
rtpcrconfirm
posit
ebov
patientdesign
inform
consent
use
ifn
exclus
criteria
includ
symptom
onset
day
prior
admiss
age
year
contraind
use
ifn
constitu
drug
product
recruit
patient
difficult
declin
outbreak
limit
proofofconcept
studi
pilot
studi
nine
patient
met
inclus
criteria
ifn
treatment
cohort
histor
control
patient
avail
comparison
treat
patient
patient
cohort
exclud
younger
year
age
onset
symptom
day
admiss
older
year
age
control
patient
admit
coyah
etu
time
period
ifn
treat
patient
rtpcrconfirm
blood
ebov
tabl
also
includ
addit
patient
match
ifntreat
patient
elig
criteria
base
day
symptom
onset
age
care
guinean
treatment
centr
better
match
baselin
ct
valu
sinc
data
avail
us
serial
ct
valu
addit
patient
vital
statu
aliv
dead
use
outcom
elig
patient
administ
ifn
ml
liquid
formul
avonex
drug
product
biogen
subcutan
daili
refer
tabl
dose
schedul
contain
x
iu
ifn
patient
treat
ifn
histor
control
receiv
support
care
avail
resourc
constrain
set
need
demand
compris
rehydr
solut
oral
ringer
lactat
solut
perfus
isoton
salt
glucos
solut
perfus
pain
fever
medic
novalgin
iv
paracetamol
oral
antalgin
oral
ortramadol
oral
plumpynut
therapeut
diet
oral
vitamin
b
complex
perfus
vitamin
c
iv
perfus
cimetidin
iv
omeprazol
oral
iv
metoclopramid
treat
symptom
gastroesophag
reflux
vogalen
iv
treat
symptom
nausea
vomit
cimetidin
iv
inhibit
stomach
acid
product
dycinon
iv
antihemorrhag
cephalosporin
antibiot
cefixim
oral
ceftriaxon
iv
antibiot
metronidazol
perfus
antimalari
coartem
oral
refer
excel
file
detail
support
care
provid
ifntreat
patient
notabl
histor
control
receiv
similar
support
care
ifntreat
patient
pain
fever
manag
case
case
basi
gastrointestin
issu
nutrit
requir
coinfect
hemorrhag
occurr
import
patient
report
whether
particip
ifn
treatment
clinic
studi
histor
control
receiv
support
care
outlin
patient
discharg
resolut
clinic
symptom
follow
consecut
neg
blood
rtpcr
result
viremia
ct
valu
hour
apart
per
guidelin
pleas
refer
studi
protocol
briefli
advers
event
report
describ
product
monograph
avonex
studi
protocol
indic
dose
adjust
withdrawl
sever
advers
event
worsen
sever
clinic
symptom
laboratori
investig
includ
serial
blood
rtpcr
analys
ebov
biochem
assay
blood
draw
edta
tube
immedi
process
determin
viremia
evd
diagnosi
made
use
semiquantit
rtpcr
assay
realstar
filoviru
screen
rtpcr
kit
altona
diagnost
gmbh
measur
express
ct
valu
cycl
threshold
invers
proport
viral
load
ct
valu
ebola
viru
posit
baselin
characterist
treatment
control
ifn
treat
group
present
median
rang
number
percentag
clinic
paramet
biochemistri
valu
symptom
comparison
two
cohort
perform
util
either
mannwhitney
test
continu
variabl
eg
ct
valu
fischer
exact
test
categor
variabl
surviv
percentag
plot
base
kaplanmei
estim
surviv
curv
compar
use
logrank
test
pvalu
shown
ifn
treatment
well
ct
valu
continu
also
test
use
wald
test
within
cox
proport
hazard
model
effect
ifn
treatment
test
adjust
model
ct
valu
assumpt
proportion
hazard
linear
ct
valu
inspect
departur
found
rate
chang
time
ct
valu
fever
well
differ
rate
ifn
treatment
control
cohort
test
util
mix
effect
model
type
model
account
possibl
correl
observ
belong
individu
inspect
residu
departur
normal
observ
differ
chang
symptom
time
treatment
group
control
investig
use
gener
estim
equat
gee
model
logit
link
specif
binari
outcom
presenc
symptom
outcom
treatment
day
interact
covari
interact
term
measur
differ
rate
chang
symptom
occurr
two
group
control
vs
ifn
treat
interact
pvalu
adjust
multipl
comparison
util
hochberg
approach
analysi
perform
use
packag
need
analysi
gee
nime
refer
fig
initi
studi
popul
includ
femal
male
age
year
coyah
treatment
unit
guinea
ebov
confirm
studi
particip
use
blood
rtpcr
import
note
ifn
avail
treatment
option
ebovinfect
individu
andor
design
right
refus
ifn
treatment
ifn
treatment
control
group
differ
age
sex
day
admiss
rel
symptom
onset
tabl
elev
alanin
aminotransferas
alt
aspart
aminotransferas
ast
creatinin
cre
c
reactiv
protein
crp
level
consist
featur
evd
studi
particip
patient
treat
ifn
start
ifn
treatment
day
postsymptom
onset
day
postsymptom
onset
one
day
postsymptom
onset
one
day
postsymptom
onset
one
patient
start
treatment
next
day
follow
admiss
treatment
unit
base
high
risk
contact
asymptomat
pcr
posit
given
elev
alt
ast
cre
level
patient
evd
unabl
determin
whether
ifn
treatment
neg
affect
biochem
blood
measur
patient
tabl
pcr
neg
result
receiv
dose
reduct
iu
relat
elev
ast
alt
level
second
consecut
pcr
neg
result
reduc
dose
anoth
patient
receiv
dose
reduct
iu
rapid
resolut
clinic
symptom
coincid
first
neg
pcr
result
patient
also
consecut
pcr
neg
result
reduc
ifn
dose
patient
treatment
discontinu
sever
clinic
symptom
subsequ
die
patient
receiv
treatment
beyond
day
becam
pcr
neg
tabl
patient
receiv
ifn
die
notabl
alt
ast
cre
significantli
elev
patient
die
despit
one
patient
exhibit
reduct
blood
viremia
ct
valu
start
ifn
treatment
ct
valu
day
patient
succumb
diseas
tabl
data
fig
show
surviv
percentag
control
day
ifn
treat
patient
day
logrank
p
hazard
ratio
hr
treatment
alon
model
p
wald
test
analysi
suggest
treatment
benefici
patient
hr
untreat
approxim
like
die
age
sex
affect
surviv
hr
ct
valu
continu
alon
model
untreat
control
cohort
p
result
indic
ct
valu
prognost
effect
larger
valu
associ
better
surviv
unit
decreas
ct
risk
death
increas
fold
model
adjust
ct
valu
effect
treatment
becom
weaker
hr
ct
slightli
stronger
hr
unit
ct
valu
increas
analysi
suggest
ct
valu
risk
die
untreat
fold
compar
ifn
treat
group
unit
decreas
ct
valu
increas
risk
die
fold
ct
valu
median
ct
probabl
die
untreat
fold
larger
treat
due
smaller
number
death
cohort
possibl
adjust
model
covari
given
recent
analysi
baselin
ct
valu
support
find
prognost
effect
extend
analysi
treatment
effect
surviv
outcom
use
expand
cohort
untreat
infect
patient
includ
addit
patient
match
ifntreat
patient
elig
criteria
base
day
symptom
onset
age
care
guinean
treatment
centr
better
match
baselin
ct
valu
notabl
patient
never
approach
particip
ifn
treatment
trial
sinc
data
avail
us
serial
ct
valu
addit
patient
use
vital
statu
aliv
dead
outcom
three
logist
regress
analys
perform
analysi
patient
includ
ifntreat
control
result
suggest
treatment
signific
even
model
adjust
ct
valu
patient
without
treatment
odd
ratio
die
fold
like
treat
adjust
ct
valu
ct
valu
median
ct
probabl
die
untreat
fold
larger
treat
tabl
ii
analysi
patient
older
year
maximum
age
ifntreat
group
baselin
ct
valu
rang
valu
ifntreat
group
exclud
patient
without
treatment
odd
ratio
die
fold
like
treat
adjust
ct
valu
ct
valu
median
ct
probabl
die
untreat
fold
larger
treat
tabl
iii
match
analysi
patient
ifntreat
group
match
group
patient
control
group
age
differ
larger
year
ct
differ
larger
patient
suitabl
match
found
ifn
one
match
ifn
one
match
ifn
three
match
ifn
two
match
ifn
three
match
ifn
ifn
ifn
ifn
match
found
enter
analysi
effect
treatment
base
condit
logist
regress
signific
p
patient
without
treatment
odd
ratio
die
fold
like
treat
probabl
die
untreat
fold
larger
treat
tabl
next
rate
viral
clearanc
blood
evalu
use
origin
control
cohort
serial
data
fig
remov
bia
associ
ct
valu
patient
succumb
diseas
ie
clear
viru
analysi
perform
patient
aliv
end
studi
ie
clear
viru
observ
trend
faster
clearanc
ifn
treat
patient
compar
control
fig
inset
ct
valu
increas
unitsday
control
unitsday
ifn
treat
patient
differ
statist
signific
p
patient
symptom
record
morn
afternoon
even
time
studi
particip
refer
tabl
frequenc
number
clinic
symptom
describ
tabl
overal
data
tabl
indic
ifn
treatment
led
earlier
resolut
mani
clinic
symptom
includ
associ
gastrointestin
dysfunct
evd
name
abdomin
pain
vomit
diarrhea
context
fever
temperatur
valu
fluctuat
studi
particip
data
shown
fever
decreas
differ
two
group
interact
pvalu
morn
afternoon
even
respect
overal
group
fever
seem
decreas
small
amount
afternoon
p
statist
signific
decreas
observ
two
group
temperatur
taken
morn
even
p
p
respect
puls
taken
afternoon
decreas
per
day
control
cohort
p
increas
per
day
ifn
treat
group
p
differ
rate
interact
term
statist
signific
p
rate
chang
morn
even
puls
chang
significantli
two
group
time
p
respect
similarli
rate
chang
systol
blood
pressur
differ
group
p
morn
p
afternoon
p
even
measur
preliminari
find
cautious
interpret
suggest
treatment
ifn
may
associ
clearanc
viru
blood
better
clinic
featur
potenti
improv
surviv
summar
consort
checklist
case
fatal
ratio
evd
associ
level
blood
viremia
find
report
herein
need
interpret
cautious
given
differ
ct
valu
control
ifn
treat
patient
limit
sampl
size
despit
limit
singl
arm
nonrandom
studi
infer
data
ifn
treatment
worthi
consider
treatment
evd
start
outbreak
ensu
month
consider
skeptic
potenti
therapeut
effect
type
ifn
strategi
outset
evalu
safeti
efficaci
ifn
treatment
henc
decis
use
nonpegyl
version
ifn
short
halflif
could
discontinu
dosereduc
rapid
clearanc
address
potenti
concern
advers
event
moreov
extens
clinic
experi
prepar
us
potenti
advers
outcom
solut
decis
undertak
trial
base
preliminari
scientif
preclin
data
perhap
pertin
absenc
approv
antivir
treat
evd
avail
cold
storag
issu
unlik
experiment
antivir
consid
recent
outbreak
uniqu
aspect
trial
onsit
team
compris
exclus
guinean
nation
healthcar
worker
receiv
first
time
relev
train
oper
administr
aspect
conduct
trial
place
guinea
team
data
analyz
util
gee
model
logit
link
ie
logist
regress
appli
symptom
binari
depend
variabl
treatment
time
covari
sinc
one
observ
patient
model
also
consid
possibl
correl
among
specifi
observ
patient
henc
gee
rather
simpl
logist
model
column
contain
effect
control
arm
effect
ifn
treat
arm
repres
symptom
chang
time
frequenc
symptom
increas
time
frequenc
symptom
decreas
time
last
column
contain
pvalu
histor
control
compar
ifntreat
patient
pvalu
indic
whether
chang
symptom
frequenc
time
differ
two
arm
highlight
valu
signific
adjust
multipl
hochberg
approach
breakdown
symptom
time
treatment
provid
tabl
individu
includ
md
administr
staff
abil
compet
conduct
clinic
trial
accord
intern
standard
although
current
outbreak
evd
west
africa
declar
januari
new
case
report
sierra
leon
ensu
day
identifi
contact
risk
develop
evd
therefor
continu
exist
possibl
resurg
evd
emerg
diverg
strain
certainli
vaccin
offer
potenti
protect
popul
resurg
ebov
strain
ident
reflect
current
vaccin
evalu
yet
remain
unclear
whether
vaccin
offer
postexposur
protect
durat
protect
prior
exposur
accordingli
need
exist
antivir
provid
broader
spectrum
activ
differ
ebov
strain
view
altogeth
data
support
evalu
ifn
treatment
evd
support
inform
protocol
interferon
protocol
pdf
tabl
match
analysi
baselin
characterist
regress
analysi
treatment
effect
surviv
patient
ifn
group
attempt
made
match
untreat
patient
less
year
differ
age
less
unit
differ
baselin
ct
valu
patient
suitabl
match
found
ifn
one
match
ifn
one
match
ifn
three
match
ifn
two
match
ifn
three
match
ifn
ifn
ifn
ifn
match
found
enter
analysi
docx
tabl
effect
ifn
frequenc
clinic
symptom
associ
evd
symptom
record
pm
e
even
indic
refer
asthenia
pm
highlight
grey
symptom
remain
rel
unchang
time
period
examin
among
histor
control
receiv
support
care
pvalu
signific
p
ifn
treat
patient
incid
asthenia
pm
decreas
time
period
arm
p
compar
histor
control
ifntreat
control
arm
fold
larger
ifntreat
arm
henc
signific
record
last
column
tabl
